{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:33:28Z","timestamp":1789011208009,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00277-023-05451-8","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T01:01:57Z","timestamp":1694739717000},"page":"3639-3641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians"],"prefix":"10.1007","volume":"102","author":[{"given":"Martin Philipp","family":"Dieterle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Mostufi-Zadeh-Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Wilhelm","family":"Kus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Wippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharias","family":"Brugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Miething","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"5451_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/ott.s370880","volume":"16","author":"T Shrivastava","year":"2023","unstructured":"Shrivastava T, Van Rhee F, Al Hadidi S (2023) Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives. Onco Targets Ther 16:441\u2013464. https:\/\/doi.org\/10.2147\/ott.s370880","journal-title":"Onco Targets Ther"},{"key":"5451_CR2","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","volume":"40","author":"P Moreau","year":"2023","unstructured":"Moreau P, van de Donk NWCJ, Delforge M et al (2023) Comparative Efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther 40:2412\u20132425. https:\/\/doi.org\/10.1007\/s12325-023-02480-7","journal-title":"Adv Ther"},{"key":"5451_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ et al (2021) Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398:665\u2013674. https:\/\/doi.org\/10.1016\/S0140-6736(21)01338-6","journal-title":"Lancet"},{"key":"5451_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/J.CLML.2023.02.006","volume":"23","author":"MV Mateos","year":"2023","unstructured":"Mateos MV, Chari A, Usmani SZ et al (2023) Comparative efficacy of teclistamab versus physician\u2019s choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 23:385\u2013393. https:\/\/doi.org\/10.1016\/J.CLML.2023.02.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5451_CR5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","volume":"101","author":"M Engelhardt","year":"2016","unstructured":"Engelhardt M, Dold SM, Ihorst G et al (2016) Geriatric assessment in multiple myeloma patients: Validation of the international Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 101:1110\u20131119. https:\/\/doi.org\/10.3324\/haematol.2016.148189","journal-title":"Haematologica"},{"key":"5451_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm AS, Dold SM et al (2017) A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102:910\u2013921. https:\/\/doi.org\/10.3324\/haematol.2016.162693","journal-title":"Haematologica"},{"key":"5451_CR7","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.34756","volume":"129","author":"TG Martin","year":"2023","unstructured":"Martin TG, Mateos MV, Nooka A et al (2023) Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma. Cancer 129:2035\u20132046. https:\/\/doi.org\/10.1002\/cncr.34756","journal-title":"Cancer"},{"key":"5451_CR8","doi-asserted-by":"publisher","first-page":"2230888","DOI":"10.1080\/07853890.2023.2230888","volume":"55","author":"Y Qi","year":"2023","unstructured":"Qi Y, Liu H, Li X et al (2023) Blinatumomab as salvage therapy in patients with relapsed\/refractory B-ALL who have failed\/progressed after anti-CD19-CAR T therapy. Ann Med 55:2230888. https:\/\/doi.org\/10.1080\/07853890.2023.2230888","journal-title":"Ann Med"},{"key":"5451_CR9","doi-asserted-by":"publisher","unstructured":"National USD of H and HS-NI of H (2017) Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/doi.org\/10.1039\/DT9930001947","DOI":"10.1039\/DT9930001947"},{"key":"5451_CR10","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.3324\/haematol.2020.266858","volume":"106","author":"L Rasche","year":"2021","unstructured":"Rasche L, W\u00e4sch R, Munder M et al (2021) Novel immunotherapies in multiple myeloma \u2013 chances and challenges. Haematologica 106:2555\u20132565","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05451-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05451-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05451-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:04:33Z","timestamp":1699679073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05451-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5451"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05451-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Profs. Drs. M. Engelhardt, R.W\u00e4sch, and C.Miething have received study support, honoraria and traveling support from Amgen, BMS, GSK, Janssen, Sanofi, Takeda. Prof. Dr. M. Engelhardt serves as the Multiple Myeloma Editor for Annals of Hematology. All other authors declare no conflicts of interest. All procedures performed were in accordance with the ethical standards of the institution UKF and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}